Last reviewed · How we verify
Megace OS
At a glance
| Generic name | Megace OS |
|---|---|
| Sponsor | Boryung Pharmaceutical Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Metronomic Chemotherapy by Cyclophosphamide Versus Megestrol in Palliative Cancer (PHASE2)
- Pharmacokinetics of Megace F and Megace OS Under Fasting and Fed Conditions in Healthy Male Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Megace OS CI brief — competitive landscape report
- Megace OS updates RSS · CI watch RSS
- Boryung Pharmaceutical Co., Ltd portfolio CI